JP2006213700A - Oxymetazoline-containing aqueous composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide nasal drop and eye drop having sustained release activities of vasoconstrictor. <P>SOLUTION: The nasal drop and the eye drop contain oxymetazoline or a salt thereof, and β-cyclodextrin or a derivative thereof. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to an aqueous composition containing oxymetazoline, which is a vasoconstrictor, and more specifically, β-cyclodextrin or a derivative thereof is blended to control the release of oxymetazoline and have a vasoconstrictive effect. It is related with the aqueous | water-based composition obtained. It can be used in the field of external preparations such as nasal drops and eye drops.

  A “vasoconstrictor” is a drug that stimulates an α-adrenergic receptor present in the blood vessel wall to cause vasoconstriction, and tetrahydrozoline, naphazoline, xylometazoline, phenylephrine and the like are known. As the “effect” of a vasoconstrictor, it is known to eliminate hyperemia and improve nasal congestion by constricting blood vessels and reducing blood flow. Usually, since the action of a vasoconstrictor is required to have an immediate effect, there has not been much study to make the action of a vasoconstrictor effective. For example, a nasal composition that has only the action of chlorpheniramine maleate, which is an antihistamine, while providing the action of a vasoconstrictor is provided (see Patent Document 1).

  However, it is a vasoconstrictor that is widely used as an active ingredient in nasal drops and eye drops because it is extremely effective in improving nasal congestion and removing hyperemia. However, it is administered frequently (abuse) because of its immediate effect. Side effects such as reactive hyperemia and drug-induced rhinitis caused by the drug cannot be ignored (see Non-Patent Document 1).

  Therefore, in order to reduce the side effects caused by frequent administration (abuse), it has become necessary to develop nasal drops and eye drops having a long-acting effect of vasoconstrictors.

JP 2004-99951 A T. Mogi et al., Allergy and Immunity, 11 (7), p934-p937, 2004

  An object of the present invention is to provide a nasal drop and an eye drop in which the action of a vasoconstrictor is sustained.

  As a result of intensive studies to solve such problems, the present inventor has found that many vasoconstrictors such as tetrahydrozoline, naphazoline, xylometazoline, phenylephrine are difficult to be sustained by the incorporation of cyclodextrin, whereas oxymeta We have found that only zoline is sustained by β-cyclodextrin or its derivatives.

  One of the embodiments of the present invention completed based on such findings is an aqueous composition containing oxymetazoline or a salt thereof and β-cyclodextrin or a derivative thereof.

  Another aspect of the present invention is the above-mentioned aqueous composition, wherein the content of β-cyclodextrin or a derivative thereof is 0.5 mol or more with respect to 1 mol of oxymetazoline.

  Another embodiment of the present invention is the above aqueous composition, wherein the derivative of β-cyclodextrin is of the hydroxypropyl type.

  The other aspect of this invention is each said aqueous composition which is a nasal drop or an eye drop.

  According to the present invention, it has become possible to provide a nasal drop or an eye drop which can selectively release oxymetazoline, which is a vasoconstrictor, and maintain its effect.

  “Oxymetazoline” is a vasoconstrictor, which may be a salt. Examples of the salt include hydrochloride and nitrate. The compounding amount of oxymetazoline is preferably 0.01 to 0.1% by mass in the aqueous composition.

  “Cyclodextrin” is a crown-shaped compound in which D-glucopyranose units are cyclically bonded by α-1,4-glucoside bonds, and is obtained by causing amylase taken from Bacillus to act on starch. The “β-cyclodextrin” of the present invention has 7 glucose units, and incorporates various cations and organic compounds into the ring to form an inclusion compound. β-cyclodextrin may be a derivative, and examples thereof include a hydroxypropyl type. The blending amount of β-cyclodextrin or a derivative thereof is 0.5 mol or more with respect to 1 mol of oxymetazoline, and 1 mol or more is preferable from the viewpoint of the long-acting effect of oxymetazoline.

  Here, “long-acting” refers to controlling so that the drug is gradually released and adjusting the pharmacological action to some extent. Synonymous with "sustained release" and "sustained".

  The aqueous composition of the present invention can be prepared by dissolving oxymetazoline, β-cyclodextrin or a derivative thereof in purified water. And it can provide as a nasal drop or an eye drop by filling this into a nasal drop container or an eye drop container.

  In that case, another active ingredient or a well-known additive can be mix | blended in the range which does not impair the effect of this invention. Other active ingredients include vasoconstrictors other than oxymetazoline, antihistamines, antiallergic agents, anti-inflammatory agents, local anesthetics, bactericides, astringents, vitamins, amino acids, sulfa drugs and the like. Known additives include pH adjusters, cooling agents, thickeners, thickeners, stabilizers, preservatives, isotonic agents, solubilizing agents, and the like.

  Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples and Test Examples.

Example 1
Oxymetazoline hydrochloride 0.05g
Ketotifen fumarate 0.075g
Benzalkonium chloride 0.01g
β-cyclodextrin 1.0 g
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount The above components were dissolved in purified water, the pH was adjusted to 4.0, and a total amount of nasal solution of 100 mL was prepared. This was filled into a nasal spray device to obtain a nasal spray.

Example 2
Oxymetazoline hydrochloride 0.05g
Chlorpheniramine maleate 0.5g
Benzalkonium chloride 0.01g
β-cyclodextrin 1.0 g
L-Menthol 0.01g
Polysorbate 80 0.02g
Ethanol 0.1mL
Citric acid appropriate amount Sodium citrate appropriate amount Glycerin appropriate amount After dissolving oxymetazoline hydrochloride, ketotifen fumarate and benzalkonium chloride in purified water, an ethanol mixed aqueous solution of polysorbate 80 in which L-menthol was dissolved was added to pH 4.0. A nasal solution having a total volume of 100 mL was prepared. This was filled into a nasal spray device to obtain a nasal spray.

Example 3
Oxymetazoline hydrochloride 0.05g
Ketotifen fumarate 0.075g
Benzalkonium chloride 0.01g
Hydroxypropyl β-cyclodextrin 0.5g
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount The above components were dissolved in purified water, the pH was adjusted to 4.0, and a total amount of nasal solution of 100 mL was prepared. This was filled into a nasal spray device to obtain a nasal spray.

Example 4
Oxymetazoline hydrochloride 0.05g
Ketotifen fumarate 0.075g
Benzalkonium chloride 0.01g
Hydroxypropyl β-cyclodextrin 1.0g
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount The above components were dissolved in purified water, the pH was adjusted to 4.0, and a total amount of nasal solution of 100 mL was prepared. This was filled into a nasal spray device to obtain a nasal spray.

Example 5
Oxymetazoline hydrochloride 0.05g
Ketotifen fumarate 0.075g
Benzalkonium chloride 0.01g
Hydroxypropyl β-cyclodextrin 2.0g
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount The above components were dissolved in purified water, the pH was adjusted to 4.0, and a total amount of nasal solution of 100 mL was prepared. This was filled into a nasal spray device to obtain a nasal spray.

Example 6
Oxymetazoline hydrochloride 0.05g
Chlorpheniramine maleate 0.5g
Benzalkonium chloride 0.01g
Hydroxypropyl β-cyclodextrin 3.0g
L-Menthol 0.01g
Polysorbate 80 0.02g
Ethanol 0.1mL
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount After dissolving oxymetazoline hydrochloride, ketotifen fumarate and benzalkonium chloride in purified water, add an ethanol mixed aqueous solution of polysorbate 80 in which L-menthol was dissolved, A nasal solution having a pH of 4.0 and a total volume of 100 mL was prepared. This was filled into a nasal spray device to obtain a nasal spray.

Example 7
Oxymetazoline hydrochloride 0.05g
Ketotifen fumarate 0.075g
Benzethonium chloride 0.004g
β-cyclodextrin 1.0 g
Gellan gum 0.2g
Polysorbate 80 0.2g
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount The above components were dissolved in purified water, and the pH was adjusted to 5.0 to prepare a total amount of nasal nasal solution. This was filled into a nasal spray device to obtain a nasal spray.

Example 8
Oxymetazoline hydrochloride 0.05g
Benzalkonium chloride 0.01g
β-cyclodextrin 1.0 g
Citric acid appropriate amount Sodium citrate appropriate amount Glycerin appropriate amount The above components were dissolved in purified water, and the pH was adjusted to 5.5 to prepare a total amount of eye drop solution of 100 mL. This was aseptically filled into an eye drop container to give an eye drop.

Example 9
Oxymetazoline hydrochloride 0.05g
Benzalkonium chloride 0.01g
Hydroxypropyl β-cyclodextrin 1.0g
Citric acid appropriate amount Sodium citrate appropriate amount Glycerin appropriate amount The above components were dissolved in purified water, and the pH was adjusted to 5.5 to prepare a total amount of eye drop solution of 100 mL. This was aseptically filled into an eye drop container to give an eye drop.

Example 10
Oxymetazoline hydrochloride 0.025g
Naphazoline hydrochloride 0.025g
Chlorpheniramine maleate 0.5g
Benzethonium chloride 0.02g
β-cyclodextrin 1.0 g
Citric acid appropriate amount Sodium citrate appropriate amount Glycerin appropriate amount The above components were dissolved in purified water, and the pH was adjusted to 4.0 to prepare a total amount of nasal solution of 100 mL. This was filled into a nasal spray device to obtain a nasal spray.

Example 11
Oxymetazoline hydrochloride 0.025g
Tetrahydrozoline hydrochloride 0.025g
Dipotassium glycyrrhizinate 0.25g
β-cyclodextrin 1.0 g
Benzalkonium chloride 0.01g
Citric acid appropriate amount Sodium citrate appropriate amount Glycerin appropriate amount The above components were dissolved in purified water, and the pH was adjusted to 5.5 to prepare a total amount of eye drop solution of 100 mL. This was aseptically filled into an eye drop container to give an eye drop.

Comparative Example 1
Oxymetazoline hydrochloride 0.05g
Ketotifen fumarate 0.075g
Benzalkonium chloride 0.01g
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount The above components were dissolved in purified water, the pH was adjusted to 4.0, and a total amount of nasal solution of 100 mL was prepared.

Comparative Example 2
Oxymetazoline hydrochloride 0.05g
Ketotifen fumarate 0.075g
Benzalkonium chloride 0.01g
α-cyclodextrin 1.0 g
Citric acid appropriate amount Sodium citrate appropriate amount D-sorbitol solution appropriate amount The above components were dissolved in purified water, the pH was adjusted to 4.0, and a total amount of nasal solution of 100 mL was prepared.

Test Example 1 In Vitro Drug Release Test [Sample] The nasal solution prepared in Comparative Example 1, Comparative Example 2, Example 1, and Example 4 was used as a sample.

[Test method] In order to evaluate the drug release from nasal drops in an in vitro system, a release test was conducted by applying the paddle method described in the Japanese Pharmacopoeia using a dissolution tester. That is, a specimen was sealed in a cellulose membrane (Dialysis Membrane, size 36: Wako Pure Chemical Industries, Ltd.) sufficiently hydrated with purified water in advance, and this was immersed in a 37 ° C. simulated nasal discharge (composition is below). Then, the amount of oxymetazoline that permeated the cellulose membrane was measured over time. The results are shown in FIGS.

[Composition of simulated nasal discharge]
NaCl 6.81g
KCl 1.91g
CaCl ₂ · 2H ₂ O 0.59 g
MgCl ₂ · _{6H 2} O 0.13g
Purified water total 1000mL
The pseudo nasal discharge was prepared with reference to the composition of “artificial nasal discharge” described in Toshiyasu Sabe et al. “Rupture of cedar pollen by nasal discharge” (Japan Public Health Magazine Vol. 39, No. 6, P341-P346). Is.

[Results] In the formulations of Example 1 and Example 4, the release of oxymetazoline was suppressed as compared with Comparative Example 1. In Comparative Example 2, the release of oxymetazoline was not suppressed.

Test example 2
[Sample] The nasal solution prepared in Comparative Example 1, Example 3, Example 4, and Example 5 was used as the sample.

[Test Method] The release of oxymetazoline was examined in the same manner as in Test Example 1. The results are shown in FIG.

[Results] Comparative Example 1 (concentration of hydroxypropyl β-cyclodextrin: 0%), Example 3 (concentration of hydroxypropyl β-cyclodextrin: 0.5%), Example 4 (hydroxypropyl β-cyclodextrin) The release of oxymetazoline was delayed depending on the concentration of cyclodextrin (concentration: 1.0%) and Example 5 (concentration of hydroxypropyl β-cyclodextrin: 1.5%).

  According to the present invention, development of nasal drops or eye drops in which the action of a vasoconstrictor is effective is expected. In addition, a new type of nasal drops that have both immediate and long-lasting effects by combining vasoconstrictors (tetrahydrozoline, naphazoline, xylometazoline, phenylephrine, etc.) that are not sustained by β-cyclodextrin or its derivatives Or the development of eye drops is expected.

It is a graph which shows the release property of the oxymetazoline in the comparative example 1, the comparative example 2, Example 1, and Example 4. FIG. It is a graph which shows the release property of the oxymetazoline in the comparative example 1, Example 3, Example 4, and Example 5. FIG.

Claims (5)

  An aqueous composition comprising oxymetazoline or a salt thereof, and β-cyclodextrin or a derivative thereof.   The aqueous composition according to claim 1, wherein the content of β-cyclodextrin or a derivative thereof is 0.5 mol or more with respect to 1 mol of oxymetazoline.   The aqueous composition according to claim 1 or 2, wherein the derivative of β-cyclodextrin is of the hydroxypropyl type.   It is a nasal drop, The aqueous composition of any one of Claims 1-3. It is an eye drop, The aqueous composition of any one of Claims 1-3.

Images